Scholarship and Biography
Jeff Warrington, Ph.D. is a senior drug discovery scientist with more than 20 years of experience across multiple areas of areas of small molecule drug research. He was centrally involved in projects that led to the invention of Reldesemtiv (now in Phase II for muscle disorders such as Spinal Muscle Atrophy), and Oxbryta (now approved for Sickle Cell Disease).
Dr. Warrington is named in over a dozen patents and publications in the field of drug discovery, and has a passion for practical use of in-silico methods to drive forward drug design. He was involved in programs that led to human drug candidates Reldesemtiv for Spinal Muscular Atrophy (SMA) and approved medication Voxelotor for Sickle Cell Disease (SCD).